AIM
RGNX icon

Alambic Investment Management’s Regenxbio RGNX Stock Holding History

Alambic Investment Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-5,463
Closed -$412K – 365
2018
Q3 		$412K Sell
5,463
-4,587
-46% -$330K 0.33% 106
2018
Q2 		$721K Buy
+10,050
New +$480K 0.2% 167

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
WM
WS Management Jacksonville, Florida $1.13B AUM 53.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Alambic Investment Management's RGNX Position: Q4 2018 in Review

Alambic Investment Management sold out of Regenxbio (RGNX) in Q4 2018, closing a stake of 5,463 shares — an estimated $412K sold.

Alambic Investment Management first reported a position in RGNX in Q2 2018 and held it in 2 quarters. The position peaked at $721K in Q2 2018. 183 funds tracked by Wall St. Rank hold RGNX as of Q4 2018.

  • Alambic Investment Management reported no remaining Regenxbio position as of Q4 2018 after selling out during the quarter.
  • Alambic Investment Management sold 5,463 Regenxbio shares in Q4 2018, an estimated $412K.
  • Alambic Investment Management first reported a position in Regenxbio in Q2 2018 and held it in 2 quarters.
  • Alambic Investment Management's Regenxbio position peaked at $721K in Q2 2018.
  • 183 funds tracked by Wall St. Rank held Regenxbio as of Q4 2018.

Based on Alambic Investment Management's 13F filing for Q4 2018, filed 12 Feb 2019.